Literature DB >> 15219942

Overexpression of DcR1 and survivin in genetically modified cells with pleiotropic drug resistance.

Irina A Davidovich1, Anait S Levenson, Victor V Levenson Chernokhvostov.   

Abstract

A previously identified set of short cDNA fragments (genetic suppressor elements, GSEs) expressed in human HT1080 cells protects them against several chemotherapeutic drugs. We show here that DNA damaging agent cytosine arabinoside can induce apoptosis in GSE-containing drug-resistant derivatives (M125 cells) of HT1080, suggesting that apoptotic pathways are preserved in M125. We also show that both parental cells and M125 constitutively express Fas ligand and TNF-related apoptosis inducing ligand, thus pre-disposing cells to apoptosis. In both cell lines, induction of apoptosis requires simultaneous treatment with low doses of cycloheximide (CHX) and death ligands, however, drug-resistant M125 are substantially more resistant to this treatment. Expression of survivin and decoy receptor 1 (DcR1) is lower in parental cells and is further decreased by CHX. In resistant M125 cell, both survivin and DcR1 are overexpressed even after CHX treatment, which can explain relative resistance of these cells. Thus, apoptosis remains intact in cells with resistance-inducing GSE, suggesting that apoptosis inhibitors can be targeted by anti-cancer therapy in drug-resistant tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15219942     DOI: 10.1016/j.canlet.2004.03.026

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.

Authors:  Giuseppina Salzano; Daniel F Costa; Can Sarisozen; Ed Luther; George Mattheolabakis; Pooja P Dhargalkar; Vladimir P Torchilin
Journal:  Small       Date:  2016-07-19       Impact factor: 13.281

2.  Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

Authors:  Delphine Mérino; Najoua Lalaoui; Alexandre Morizot; Pascal Schneider; Eric Solary; Olivier Micheau
Journal:  Mol Cell Biol       Date:  2006-10       Impact factor: 4.272

3.  TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT.

Authors:  Najoua Lalaoui; Aymeric Morlé; Delphine Mérino; Guillaume Jacquemin; Elisabetta Iessi; Alexandre Morizot; Sarah Shirley; Bruno Robert; Eric Solary; Carmen Garrido; Olivier Micheau
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

Review 4.  Death receptors as targets in cancer.

Authors:  O Micheau; S Shirley; F Dufour
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

5.  Tumor cell-selective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody.

Authors:  Franziska Hartung; Walter Stühmer; Luis A Pardo
Journal:  Mol Cancer       Date:  2011-09-07       Impact factor: 27.401

6.  TRAIL Is Decreased Before 20 Weeks Gestation in Women with Hypertensive Disorders of Pregnancy.

Authors:  Cheng Zhou; Yan Long; Hongling Yang; Chunyan Zhu; Qingling Ma; Yonggang Zhang
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

7.  Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.

Authors:  Leszek Gottwald; Janusz Piekarski; Robert Kubiak; Jarosław Szwalski; Grażyna Pasz-Walczak; Piotr Sęk; Michał Spych; Jacek Suzin; Wiesław Tyliński; Arkadiusz Jeziorski
Journal:  Arch Gynecol Obstet       Date:  2013-04-13       Impact factor: 2.344

8.  Epigonal conditioned media from bonnethead shark, Sphyrna tiburo, induces apoptosis in a T-cell leukemia cell line, Jurkat E6-1.

Authors:  Catherine J Walsh; Carl A Luer; Jennifer E Yordy; Theresa Cantu; Jodi Miedema; Stephanie R Leggett; Brittany Leigh; Philip Adams; Marissa Ciesla; Courtney Bennett; Ashby B Bodine
Journal:  Mar Drugs       Date:  2013-08-26       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.